|
Title |
NIHR ref |
RLBUHT RD&I |
LSTM RD&I |
REC EudraCT |
Primary objective |
Where Archived |
Funder |
|
EHPC: The effect of age on immune function |
20792 | 5174 | 15-053 | 16/NW/0031 | Detection of S. pneumoniae by classical bacteria culture methods from one or more nasal wash sample in the first 14 days following initial pneumococcal challenge. | MRC | |
|
EHPC: The effect of asthma on immune response to Pneumococcus Started 2016 |
20857 | 5173 | 16-010 | 16/NW/0124 |
To determine the rate of EHPC acquisition in people with asthma To study the systemic and mucosal immune responses To determine the protective effect of carriage against reacquisition of carriage |
MRC | |
| EHPC: Hand to nose transmission of streptococcus pneumoniae in healthy participants – pilot study Started 2017 33503 |
33503 | 5376 | 16-069 | 17/NW/0054 | To determine the feasibility of Experimental Pneumococcal Carriage acquisition following pneumococcal transmission from hand to nostrils. |
MRC and Pharma: |
|
| EHPC: Hand Wash Study Started 2017 |
N/A | 17-077 |
17/NW/0658 | To evaluate if hand washing with antimicrobial soap affects hand to nose transmission of Streptococcus pneumoniae leading to nasal colonisation |
Pharma: Unilever |
||
|
Testing new strains in the EHPC Model Started 2017 20815 |
5124 | 15-051 | 15/NW/0931 | To establish experimental human carriage with a non-vaccine and 23F serotype pneumococcus.
To determine the protective effect of carriage against reacquisition of carriage following inoculation with a different pneumococcal strain. |
MRC | ||
|
EHPC The Effect of Live Attenuated Influenza Vaccine (LAIV) on EHPC Started 2016 |
4896 |
14-058 |
14/NW/1460
EudraCT 2014-004634-26 |
To define the effect of LAIV on pneumococcal colonisation using the EHPC model in order to assess the potential effects of mass influenza vaccination. We will measure colonisation acquisition, density and duration. |
|
MRC and Gates Foundation |
|
|
EHPC Pilot study of repeated mucosal sampling on experimental human pneumococcal colonization Started 2015 |
|
4938 |
15-027 |
15/NW/0146 |
To evaluate if repeated mucosal sampling will obtain sufficient tissue for immunological assessment.
|
|
|
|
Genocea (phase 2) pneumococcal otitis media vaccine Started 2014 |
17331 |
4741 |
14-058 |
14/NW/0355 |
To evaluate the effect of Gen-004 on pneumococcal colinazation compared to placebo. |
RLBUHT |
Pharma: GENOCEA |
|
PCV EHPC Started 2013 |
13932 |
4431 |
|
12/NW/0873
EudraCT 2012-005141-20 |
To evaluate the effect of PCV on pneumococcal colonization compared to Hep A vaccine (Avaxim). |
|
Gates Foundation |
|
Dose ranging and reproducibility Started 2011 |
11731 |
4210 |
|
11/NW/0592 |
To establish >40% pneumococcal colonization using 6B and 23F creating a dose range curve and to validate the model by reproducing the findings. |
|
BM Gates Foundation
|